Description
Cardiovascular disease remains a major cause of death and disability in developed countries and, increasingly so, in the developing world. This is driven in part by demographics and the increase in longevity, and the obesity-metabolic syndrome-diabetes-atherosclerosis continuum that is reaching pandemic proportions. Accordingly, the discovery of novel targets involved in cardiovascular disease, and the design of small molecules or biologics that interact with these sites, still holds the greatest promise for treating large numbers of individuals afflicted with these conditions. Presented in this volume of Advances in Pharmacology are some of the most promising possibilities in that regard.
